BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dummer R, Prince HM, Whittaker S, Horwitz SM, Kim YH, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Eradat H, Pinter-Brown L, Sanches JA, Ortiz-Romero PL, Akilov OE, Geskin L, Huen A, Walewski J, Wang Y, Lisano J, Richhariya A, Feliciano J, Zhu Y, Bunn V, Little M, Zagadailov E, Dalal MR, Duvic M. Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study. Eur J Cancer 2020;133:120-30. [PMID: 32502876 DOI: 10.1016/j.ejca.2020.04.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Zinzani PL, Quaglino P, Violetti SA, Cantonetti M, Goteri G, Onida F, Paulli M, Rupoli S, Barosi G, Pimpinelli N. Critical concepts and management recommendations for cutaneous T-cell lymphoma: A consensus-based position paper from the Italian Group of Cutaneous Lymphoma. Hematol Oncol 2021;39:275-83. [PMID: 33855728 DOI: 10.1002/hon.2832] [Reference Citation Analysis]
2 Podkonjak T, Cranmer H, Scarisbrick J, McCarthy G, Lilley C, Cheng LI. Cost-effectiveness of brentuximab vedotin for the treatment of cutaneous T-cell lymphoma. J Comp Eff Res 2021. [PMID: 34879742 DOI: 10.2217/cer-2021-0201] [Reference Citation Analysis]
3 Dummer R, Vermeer MH, Scarisbrick JJ, Kim YH, Stonesifer C, Tensen CP, Geskin LJ, Quaglino P, Ramelyte E. Cutaneous T cell lymphoma. Nat Rev Dis Primers 2021;7:61. [PMID: 34446710 DOI: 10.1038/s41572-021-00296-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Kim YH. What factors guide treatment selection in mycosis fungoides and Sezary syndrome? Hematology Am Soc Hematol Educ Program 2021;2021:303-12. [PMID: 34889422 DOI: 10.1182/hematology.2021000263] [Reference Citation Analysis]
5 El Bairi K, Al Jarroudi O, Afqir S. Revisiting antibody-drug conjugates and their predictive biomarkers in platinum-resistant ovarian cancer. Semin Cancer Biol 2021:S1044-579X(21)00081-X. [PMID: 33812984 DOI: 10.1016/j.semcancer.2021.03.031] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Velasco R, Domingo-Domenech E, Sureda A. Brentuximab-Induced Peripheral Neurotoxicity: A Multidisciplinary Approach to Manage an Emerging Challenge in Hodgkin Lymphoma Therapy. Cancers (Basel) 2021;13:6125. [PMID: 34885234 DOI: 10.3390/cancers13236125] [Reference Citation Analysis]
7 Dippel E, Assaf C, Becker JC, von Bergwelt-Baildon M, Bernreiter S, Cozzio A, Eich HT, Elsayad K, Follmann M, Grabbe S, Hillen U, Klapper W, Klemke CD, Loquai C, Meiss F, Mitteldorf C, Wehkamp U, Nashan D, Nicolay JP, Oschlies I, Schlaak M, Stranzenbach R, Moritz R, Stoll C, Vag T, Weichenthal M, Wobser M, Stadler R. S2k-Leitlinie - Kutane Lymphome (ICD10 C82-C86): Update 2021. J Dtsch Dermatol Ges 2022;20:537-55. [PMID: 35446484 DOI: 10.1111/ddg.14706_g] [Reference Citation Analysis]
8 Porcu P, Hudgens S, Horwitz S, Quaglino P, Cowan R, Geskin L, Beylot-Barry M, Floden L, Bagot M, Tsianakas A, Moskowitz A, Huen A, Dreno B, Dalle S, Caballero D, Leoni M, Dale S, Herr F, Duvic M. Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma. Clin Lymphoma Myeloma Leuk 2021;21:97-105. [PMID: 33158772 DOI: 10.1016/j.clml.2020.09.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
9 Nawar T, Elsayad K, Müller EC, Rolf D, Moritz RKC, Bormann E, Weishaupt C, Stranzenbach R, Stadler R, Moustakis C, Assaf C, Livingstone E, Sunderkötter C, Steinbrink K, Eich HT. Quality of life in patients with mycosis fungoides and Sézary syndrome undergoing low-dose total skin electron beam therapy with or without maintenance therapy. J Am Acad Dermatol 2021:S0190-9622(21)00564-8. [PMID: 33722549 DOI: 10.1016/j.jaad.2021.03.025] [Reference Citation Analysis]
10 Dippel E, Assaf C, Becker JC, von Bergwelt-Baildon M, Bernreiter S, Cozzio A, Eich HT, Elsayad K, Follmann M, Grabbe S, Hillen U, Klapper W, Klemke CD, Loquai C, Meiss F, Mitteldorf C, Wehkamp U, Nashan D, Nicolay JP, Oschlies I, Schlaak M, Stranzenbach R, Moritz R, Stoll C, Vag T, Weichenthal M, Wobser M, Stadler R. S2k-Guidelines - Cutaneous lymphomas (ICD10 C82 - C86): Update 2021. J Dtsch Dermatol Ges 2022;20:537-54. [PMID: 35446497 DOI: 10.1111/ddg.14706] [Reference Citation Analysis]